TREACE MEDICAL CONCEPTS, INC.
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
TMCI$4.03-3.6%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share and per share amounts)
| March 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $13,372 | $11,350 |
| Marketable securities, short-term | 62,717 | 64,327 |
| Accounts receivable, net of allowance for credit losses of $1,441 and $1,326 as of March 31, 2025 and December 31, 2024, respectively | 31,110 | 40,803 |
| Inventories | 37,940 | 39,255 |
| Prepaid expenses and other current assets | 4,298 | 5,667 |
| Total current assets | 149,437 | 161,402 |
| Property and equipment, net | 27,129 | 25,953 |
| Intangible assets, net of accumulated amortization of $1,663 and $1,425 as of March 31, 2025 and December 31, 2024, respectively | 7,837 | 8,075 |
| Goodwill | 12,815 | 12,815 |
| Operating lease right-of-use assets | 8,241 | 8,442 |
| Other non-current assets | 387 | 407 |
| Total assets | $205,846 | $217,094 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $13,223 | $10,522 |
| Accrued liabilities | 6,008 | 7,197 |
| Accrued commissions | 6,529 | 10,121 |
| Accrued compensation | 5,190 | 6,575 |
| Other liabilities | 2,230 | 510 |
| Total current liabilities | 33,180 | 34,925 |
| Long-term debt, net | 53,380 | 53,306 |
| Operating lease liabilities, net of current portion | 13,908 | 15,934 |
| Other long-term liabilities | 37 | 37 |
| Total liabilities | 100,505 | 104,202 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.001 par value, 5,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 0 shares issued as of March 31, 2025 and December 31, 2024 | — | — |
| Common stock, $0.001 par value, 300,000,000 shares authorized; 62,967,502 and 62,385,101 shares issued as of March 31, 2025 and December 31, 2024, respectively | 63 | 62 |
| Additional paid-in capital | 311,815 | 303,004 |
| Accumulated deficit | (205,912) | (189,990) |
| Accumulated other comprehensive (loss) income | 57 | 97 |
| Treasury stock, at cost; 75,996 and 23,391 shares as of March 31, 2025 and December 31, 2024, respectively | (682) | (281) |
| Total stockholders’ equity | 105,341 | 112,892 |
| Total liabilities and stockholders’ equity | $205,846 | $217,094 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.